A clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients

被引:20
|
作者
Gao, Yin-jie [1 ,2 ]
Zhang, Min [2 ]
Jin, Bo [2 ]
Meng, Fan-ping [2 ]
Ma, Xue-mei [2 ]
Liu, Zhen-wen [2 ]
Su, Hai-bin [2 ]
Zhao, Jing-min [2 ]
Li, Han-wei [2 ]
机构
[1] Chinese PLA, Sch Med, Beijing, Peoples R China
[2] 302 Mil Hosp, Dept Infect Dis, Beijing 100039, Peoples R China
关键词
entecavir; hepatitis B; lamivudine; liver transplantation; recurrence; PREVENT HBV RECURRENCE; IMMUNE GLOBULIN; GRAFT REINFECTION; UNITED-STATES; LAMIVUDINE; ENTECAVIR; PROPHYLAXIS; INFECTION; DISEASE; IMMUNOGLOBULIN;
D O I
10.1111/jgh.12404
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimLiver transplantation (LT) for hepatitis B virus (HBV)-related disease can be complicated by HBV recurrence. The aim of this study was to evaluate the risk factors, prophylaxis treatment, and histological characteristics of HBV recurrence after LT when using long-term, low-dose hepatitis B immunoglobulin (HBIG) plus nucleoside analog (lamivudine [LAM] or entecavir [ETV]). MethodsRetrospective data from 253 adult LT patients using long-term, low-dose HBIG plus nucleoside analog after LT, for a mean treatment duration of 1-72 months, were collected from a single center in Beijing, China. Univariate analyses were conducted to determine the association among gender, age, hepatocellular carcinoma, hepatitis B e antigen-positive status, HBV-DNA level and tyrosine-methionine-aspartate-aspartate (YMDD) mutations on HBV recurrence in these patients. ResultsOverall, the HBV recurrence rate was 6.32% (16/253). There was no significant difference in the survival rate between the HBV recurrence and non-recurrence groups. Risk factors for HBV recurrence were: hepatitis B e antigen positivity, HBV-DNA >10(5) copies/mL, hepatocellular carcinoma, and YMDD mutation. Sixteen patients receiving LAM had HBV recurrence (16/169; mean treatment duration: 61.818.3 months). No HBV recurrence occurred in patients receiving ETV after LT (0/84; mean treatment duration: 57.1 +/- 15.9 months). Differences in rate of mortality and HBV recurrence were not significant between the two groups. ConclusionsLT is an effective treatment for HBV-related end-stage liver disease. The combination of ETV and intramuscular HBIG for HBV recurrence prophylaxis after LT was more effective than LAM, especially in Chinese patients with HBV recurrence risk factors.
引用
收藏
页码:554 / 560
页数:7
相关论文
共 50 条
  • [21] Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta-analysis
    Lai, Quirino
    Mennini, Gianluca
    Giovanardi, Francesco
    Rossi, Massimo
    Giannini, Edoardo G.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (08)
  • [22] Liver transplantation and hepatitis B virus infection: towards an immunoglobulin-free antiviral treatment after transplantation
    Chan, Albert C. Y.
    Fung, James Y. Y.
    Lo, Chung Mau
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2016, 21 (02) : 219 - 223
  • [23] Hepatitis B and liver transplantation: Update in management before and after transplantation
    Chang M.S.
    Brown Jr. R.S.
    Current Hepatitis Reports, 2011, 10 (4) : 255 - 261
  • [24] Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation
    Na, Gun Hyung
    Kim, Dong Goo
    Han, Jae Hyun
    Kim, Eun Young
    Lee, Soo Ho
    Hong, Tae Ho
    You, Young Kyoung
    Choi, Jong Young
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (01) : 151 - 156
  • [25] Recent advances in prevention of hepatitis B recurrence after liver transplantation
    Zhi-Feng Xi
    Qiang Xia
    World Journal of Gastroenterology, 2015, (03) : 829 - 835
  • [26] The role of entecavir in preventing hepatitis B recurrence after liver transplantation
    Xi, Zhi Feng
    Xia, Qiang
    Zhang, Jian Jun
    Chen, Xiao Song
    Han, Long Zhi
    Wang, Xin
    Shen, Cong Huan
    Luo, Yi
    Xin, Tian Yu
    Wang, Si Yue
    Qiu, De Kai
    JOURNAL OF DIGESTIVE DISEASES, 2009, 10 (04) : 321 - 327
  • [27] Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation
    Jiang, Li
    Jiang, Li-Sheng
    Cheng, Nan-Sheng
    Yan, Lu-Nan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (20) : 2489 - 2499
  • [28] Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation
    Yuefeng, M.
    Weili, F.
    Wenxiang, T.
    Ligang, X.
    Guiling, L.
    Hongwei, G.
    Wencai, L.
    Xiaoguang, W.
    Wei, M.
    Zhongyi, F.
    CLINICAL TRANSPLANTATION, 2011, 25 (04) : 517 - 522
  • [29] Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis
    Marzano, A
    Salizzoni, M
    Debernardi-Venon, W
    Smedile, A
    Franchello, A
    Ciancio, A
    Gentilcore, E
    Piantino, P
    Barbui, AM
    David, E
    Negro, F
    Rizzetto, M
    JOURNAL OF HEPATOLOGY, 2001, 34 (06) : 903 - 910
  • [30] Liver transplantation in patients with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus
    Duclos-Vallee, Jean-Charles
    Roche, Bruno
    Samuel, Didier
    PRESSE MEDICALE, 2009, 38 (09): : 1281 - 1289